NASDAQ:STIM Neuronetics (STIM) Stock Price, News & Analysis → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free STIM Stock Alerts $2.60 -1.15 (-30.67%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$2.39▼$3.5950-Day Range$2.60▼$4.8152-Week Range$1.03▼$5.07Volume988,460 shsAverage Volume181,378 shsMarket Capitalization$77.95 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Neuronetics alerts: Email Address Neuronetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside207.7% Upside$8.00 Price TargetShort InterestHealthy0.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.01Based on 15 Articles This WeekInsider TradingSelling Shares$451,206 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.92) to ($0.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.40 out of 5 starsMedical Sector417th out of 903 stocksSurgical & Medical Instruments Industry53rd out of 95 stocks 3.3 Analyst's Opinion Consensus RatingNeuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeuronetics has only been the subject of 2 research reports in the past 90 days.Read more about Neuronetics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the outstanding shares of Neuronetics have been sold short.Short Interest Ratio / Days to CoverNeuronetics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neuronetics has recently decreased by 39.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeuronetics does not currently pay a dividend.Dividend GrowthNeuronetics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STIM. Previous Next 1.1 News and Social Media Coverage News SentimentNeuronetics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Neuronetics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $451,206.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Neuronetics is held by insiders.Percentage Held by Institutions53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neuronetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Neuronetics are expected to grow in the coming year, from ($0.92) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neuronetics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neuronetics is -2.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeuronetics has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Neuronetics Stock (NASDAQ:STIM)Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.Read More STIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STIM Stock News HeadlinesMay 8, 2024 | markets.businessinsider.comBuy Rating on Neuronetics: Solid Fundamentals and Growth Despite ChallengesMay 8, 2024 | finance.yahoo.comNeuronetics Inc (STIM) (Q1 2024) Earnings Call Transcript Highlights: Strategic Growth Amidst ...May 8, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 8, 2024 | wsj.comNeuronetics Inc.May 7, 2024 | msn.comNeuronetics GAAP EPS of -$0.27 beats by $0.04, revenue of $17.42M beats by $0.3MMay 7, 2024 | msn.comSTIM Stock Earnings: Neuronetics Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comNeuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing LossesMay 7, 2024 | globenewswire.comNeuronetics Reports Record First Quarter 2024 Financial and Operating ResultsMay 8, 2024 | Unstoppable Prosperity (Ad)RSVP: Charles Payne’s Cash Flow WorkshopAre you ready to find untapped value in the stocks you already own… Without selling a single share… Then you need to know these Cash Flow Trade Strategies.May 6, 2024 | msn.comNeuronetics Q1 2024 Earnings PreviewMay 5, 2024 | americanbankingnews.comNeuronetics (STIM) to Release Quarterly Earnings on TuesdayMay 4, 2024 | finance.yahoo.comNeuronetics, Inc. (STIM)May 4, 2024 | msn.comNeuronetics Awards Stock Options to New Employees as InducementMay 3, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comNeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness MonthApril 25, 2024 | msn.comNeuronetics Announces Q1 2024 Earnings Release and Conference CallApril 23, 2024 | globenewswire.comNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallApril 12, 2024 | msn.comNew Study Offers Hope for Depression Patients Undergoing TMS TherapyApril 10, 2024 | globenewswire.comNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalApril 5, 2024 | benzinga.comNeuronetics Stock (NASDAQ:STIM), Quotes and News SummaryApril 1, 2024 | msn.comNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresMarch 29, 2024 | msn.comFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive DisorderMarch 27, 2024 | finance.yahoo.comNeuronetics wins FDA clearance for device to treat adolescents with depressionMarch 27, 2024 | finance.yahoo.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | globenewswire.comNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 27, 2024 | markets.businessinsider.comBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketMarch 25, 2024 | msn.comNeuronetics’s NeuroStar wins FDA clearance for adolescents with depressionSee More Headlines Receive STIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/07/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:STIM CUSIPN/A CIK1227636 Webwww.neurostar.com Phone(610) 640-4202Fax610-640-4206Employees203Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+207.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,190,000.00 Net Margins-42.31% Pretax Margin-42.31% Return on Equity-72.76% Return on Assets-29.25% Debt Debt-to-Equity Ratio1.73 Current Ratio4.73 Quick Ratio4.33 Sales & Book Value Annual Sales$71.35 million Price / Sales1.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book2.20Miscellaneous Outstanding Shares29,980,000Free Float27,037,000Market Cap$77.95 million OptionableOptionable Beta2.50 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Keith J. Sullivan (Age 66)President, CEO & Director Comp: $1.39MMr. Stephen J. Furlong M.S. (Age 60)Executive VP, CFO & Treasurer Comp: $771.38kMr. W. Andrew Macan (Age 51)Executive VP, GC, Chief Compliance Officer & Corporate Secretary Comp: $629.7kMr. Rusty PageSenior VP of Operations & QualityMs. Lisa Metzner-RosasSenior VP & Chief Marketing OfficerMs. Sara GrubbsSenior VP & Chief Revenue OfficerMr. Rick GrubbsSenior Vice President of National AccountsMr. Cory S. AndersonSenior Vice President of R&D and ClinicalMore ExecutivesKey CompetitorsenVVeno MedicalNASDAQ:NVNOSEP AcquisitionNASDAQ:SEPAMonogram OrthopaedicsNASDAQ:MGRMSensus HealthcareNASDAQ:SRTSPro-DexNASDAQ:PDEXView All CompetitorsInsiders & InstitutionsSG Americas Securities LLCBought 13,048 shares on 5/7/2024Ownership: 0.044%Assenagon Asset Management S.A.Sold 2,866 shares on 4/24/2024Ownership: 0.278%David J Yvars GroupSold 5,210 shares on 4/11/2024Ownership: 0.234%William Andrew MacanSold 22,377 sharesTotal: $70,711.32 ($3.16/share)Stephen FurlongSold 21,272 sharesTotal: $70,835.76 ($3.33/share)View All Insider TransactionsView All Institutional Transactions STIM Stock Analysis - Frequently Asked Questions Should I buy or sell Neuronetics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" STIM shares. View STIM analyst ratings or view top-rated stocks. What is Neuronetics' stock price target for 2024? 2 analysts have issued 12 month price targets for Neuronetics' shares. Their STIM share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 207.7% from the stock's current price. View analysts price targets for STIM or view top-rated stocks among Wall Street analysts. How have STIM shares performed in 2024? Neuronetics' stock was trading at $2.90 at the beginning of 2024. Since then, STIM stock has decreased by 10.3% and is now trading at $2.60. View the best growth stocks for 2024 here. Are investors shorting Neuronetics? Neuronetics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 57,700 shares, a decrease of 39.0% from the March 31st total of 94,600 shares. Based on an average daily trading volume, of 170,500 shares, the days-to-cover ratio is currently 0.3 days. View Neuronetics' Short Interest. How were Neuronetics' earnings last quarter? Neuronetics, Inc. (NASDAQ:STIM) announced its earnings results on Tuesday, March, 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. The firm had revenue of $20.31 million for the quarter, compared to the consensus estimate of $19.73 million. Neuronetics had a negative net margin of 42.31% and a negative trailing twelve-month return on equity of 72.76%. During the same quarter in the previous year, the business posted ($0.30) earnings per share. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics issued an update on its second quarter 2024 earnings guidance on Wednesday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.0 million-$19.0 million, compared to the consensus revenue estimate of $19.5 million. What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST). When did Neuronetics IPO? Neuronetics (STIM) raised $75 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.28%), David J Yvars Group (0.23%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan. View institutional ownership trends. How do I buy shares of Neuronetics? Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STIM) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsAI “wealth window” is closing June 25thParadigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
